Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 165
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00741819 | Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects | ||
| NCT02318186 | Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) | ||
| NCT02360345 | Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly | ||
| NCT07261241 | NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | ||
| NCT04850105 | A Non-interventional Cohort Safety Study of Patients With hATTR-PN | ||
| NCT04827056 | Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study | ||
| NCT00458042 | Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction | ||
| NCT02999906 | Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension | ||
| NCT01560624 | Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy | ||
| NCT01043627 | Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) | ||
| NCT03481725 | Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Department of Defense Funded Multicenter Pilot Study | ||
| NCT01165476 | Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities | ||
| NCT01266265 | Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies | ||
| NCT06223009 | Phase 1 Healthy Volunteer Burn Therapy Study | ||
| NCT00373360 | Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin | ||
| NCT06388421 | DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | ||
| NCT02573896 | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | ||
| NCT05245006 | PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | ||
| NCT06477640 | Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension | ||
| NCT01588405 | Remodulin® to Oral Treprostinil Transition | ||
| NCT00848107 | Open-Label Study of Oral Treprostinil in Digital Ulcers | ||
| NCT03055221 | TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) | ||
| NCT01007890 | Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer | ||
| NCT01557660 | Inhaled Treprostinil for PAH: Open-label Extension | ||
| NCT04411680 | Study of Sargramostim in Patients With COVID-19 | ||
| NCT01131845 | The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil | ||
| NCT04050449 | Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD | ||
| NCT01746485 | Three Times Daily Dosing of UT-15C | ||
| NCT02370095 | Treprostinil Sodium Inhalation for Patients At High Risk for ARDS | ||
| NCT02693171 | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients | ||
| NCT01321073 | DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study | ||
| NCT01477333 | Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® | ||
| NCT01566877 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers | ||
| NCT06964009 | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | ||
| NCT02882126 | An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension | ||
| NCT05848687 | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | ||
| NCT01172496 | A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers | ||
| NCT02630316 | Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE | ||
| NCT00439946 | Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH | ||
| NCT07116681 | Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | ||
| NCT01028651 | A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension | ||
| NCT01268553 | Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication | ||
| NCT01260454 | The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain | ||
| NCT03367312 | Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI | ||
| NCT02279745 | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension | ||
| NCT03794583 | Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) | ||
| NCT00887978 | Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension | ||
| NCT03496623 | A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) | ||
| NCT00494533 | Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension | ||
| NCT00325442 | FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) |
